Problem Device Approach Impact Team Get in Touch
Lumenate Medical

Bladder cancer
doesn't wait.
Neither should
screening.

Expanding access to life-saving bladder cancer screening — making it available everywhere, not only where specialists practice.

See how it works Get in touch
Supported by
JHU Engineering JHU CBID JHU Medicine Abell Foundation AUA Innovation Nexus Venturewell Pioneer Propel TU Startup
The Problem

Millions wait months
for screening that
could save their life.

Bladder cancer is most treatable when caught early, yet the specialists who screen for it are concentrated in a shrinking number of places. For most patients, access depends on geography and a long wait for an appointment.

$0B
Annual burden to the healthcare system
0%
Of U.S. counties have no practicing urologist
0M
Present annually with symptoms warranting cystoscopy evaluation
The Device

Designed for the
point of care.

Lumenate's catheter-based cystoscope is being designed for non-urologists. It is designed to capture the images urologists need — without a urologist in the room, and without taking them out of the loop.

Our Approach

Enabling providers already in every community to deliver the screening patients need.

Lumenate Medical aims to enable non-urologist providers — Physician Associates and Nurse Practitioners — to perform bladder cancer screening, with specialist oversight built in. Multiplying what the existing urology workforce can reach.

Step 01
Image collection by non-urologist providers, such as PAs & NPs
Community providers use Lumenate's device to capture cystoscopy images with minimal training and built-in guidance.
Step 02
Asynchronous image review by urologists
Board-certified urologists review images remotely on their schedule — no patient visit required.
Impact
Faster results, earlier diagnosis
The goal: patients receive results in days, not months.
Impact

Better outcomes for everyone in the system.

Earlier diagnosis and expanded access are projected to create measurable value for patients, providers, practices, and payers alike.

Payers
$0B
Reduction in annual payer expenditure by diagnosing one stage earlier
Patients
0%
Reduction in patient out-of-pocket costs vs. late-stage diagnoses
Urologists
0+ hrs
Freed per year, per urologist, for higher-complexity procedures
Practices
$0M
In added annual revenue from task-shifting cystoscopy to non-urologist providers

Figures shown are projected estimates based on internal modeling and published literature, not results from a clinical study.

Team

The people
behind Lumenate.

Haley Slosberg
Haley Slosberg, M.S.E.
Co-Founder
Chief Executive Officer
Jack Darbonne
Jack Darbonne, M.S.E.
Co-Founder
Chief Technology Officer
Anand Vaish
Anand Vaish, M.S.E.
Co-Founder
Chief Operating Officer
Dr. Arun Rai
Dr. Arun Rai, M.D., M.B.A.
Head of Clinical
Exited Founder, Johns Hopkins Urologist
Advisors
Dr. Mohammad Allaf
Dr. Mohammad Allaf, M.D.
Advisor
Urologist-in-Chief and Director, Department of Urology, Johns Hopkins
Jee Shin
Jee Shin, M.B.A.
Advisor
Founder, Calyxo, Inc.
Get in Touch

Let's talk.

Interested in partnering, investing, or learning more about Lumenate Medical? We'd love to hear from you.